Ładuje się......
Use of pembrolizumab in MSI-high uterine leiomyosarcoma; a case report and review of the literature
• Overall prognosis of uterine leiomyosarcoma (ULMS) is poor with a low 5-year survival rate. • Microsatellite instability (MSI)-high ULMS is not well documented in current literature. • Immune checkpoint inhibitors such as pembrolizumab have been shown to have good efficacy in treating MSI-high sol...
Zapisane w:
| Wydane w: | Gynecol Oncol Rep |
|---|---|
| Główni autorzy: | , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Elsevier
2021
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7843391/ https://ncbi.nlm.nih.gov/pubmed/33537390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2021.100701 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|